Pharmacokinetic Comparability Study of Pre- and Post-change Teclistamab in Relapsed/Refractory Multiple Myeloma Patients

The primary objective of this study is to evaluate the **pharmacokinetic comparability** of pre- and post-change **teclistamab** in participants with **relapsed/refractory multiple myeloma**. This is clinically relevant as it aims to ensure that any modifications to the formulation or manufacturing process of teclistamab do not affect its pharmacokinetic profile, which is crucial for maintaining therapeutic efficacy and safety in this patient population.

The clinical trial involves a total of **52 participants** diagnosed with **Relapsed/Refractory Multiple Myeloma**. The study population includes both male and female subjects, with an age range encompassing adults and older adults. Participants were selected to include a vulnerable population, although specific selection criteria are not provided. The trial does not specify any particular lifestyle considerations such as diet or physical activity. The sponsor has not disclosed detailed inclusion or exclusion criteria for this study.

The clinical trial is designed as a **Phase 1** randomized, open-label pharmacokinetic comparability study. It aims to evaluate the pharmacokinetics of pre- and post-change **teclistamab** in participants diagnosed with **relapsed/refractory multiple myeloma**. The trial is scheduled to commence recruitment on July 30, 2024, and is expected to conclude by January 2, 2027. Participants will be randomly assigned to receive either the pre-change or post-change formulation of the investigational product, with the open-label design allowing both participants and investigators to be aware of the treatment allocation.

The study will involve a series of visits, beginning with an inclusion (screening) visit to assess eligibility based on predefined criteria. Following successful screening, participants will undergo baseline assessments before the initiation of treatment. Subsequent follow-up visits will be conducted at regular intervals to monitor safety, efficacy, and pharmacokinetic parameters. The end-of-study visit will occur after the final treatment cycle, where comprehensive evaluations will be performed to gather data on the long-term effects and overall outcomes of the treatment.

Participant involvement is expected to last throughout the trial duration, with specific timelines for each phase of the study. Conditions that may lead to early termination from the study include adverse events, withdrawal of consent, or any protocol deviations that compromise the integrity of the trial. The study is structured to ensure rigorous data collection and analysis, contributing valuable insights into the pharmacokinetic profile of teclistamab in the specified patient population.

The clinical trial documentation does not provide specific details regarding the experimental medication, including its name, pharmaceutical form, dosage, route, or frequency of administration. As such, no detailed description of the experimental treatment can be provided based on the available data.

Similarly, there is no information available about any non-experimental treatments used in the study, such as standard-of-care therapy, placebo, or comparator treatment. Consequently, no description of these treatments can be included.

Additional relevant information about drug administration, dosing schedules, and participant compliance monitoring is also not provided in the source data. Therefore, no further details can be elaborated upon in this context.

The clinical trial is designed to assess efficacy in a Phase 3 study. The trial is scheduled to commence recruitment on July 30, 2024, with an estimated completion date of January 2, 2027. The efficacy assessment will be conducted through a series of planned evaluations, although specific parameters or endpoints for efficacy evaluation are not detailed in the available data. The trial will follow a structured timeline to ensure systematic data collection and analysis, adhering to the rigorous standards expected in a Phase 3 clinical trial. The methodology for measuring and analyzing efficacy will be aligned with standard clinical practices, ensuring the reliability and validity of the results. The trial's design and execution will focus on generating robust data to support the evaluation of the investigational product's efficacy.